The case for & against
Bull & Bear analysis
Stryker Corporation (NYSE: SYK) is a leading global medical technology company primarily engaged in developing and manufacturing innovative surgical devices, especially in orthopedics, medical surgical equipment, and neurotechnology. The company is marketed by its strong focus on robotics, particularly with its Mako robotic system, making substantial inroads in addressing surgical efficiency and enhancing patient outcomes. Stryker operates in a dynamic and competitive landscape, leveraging its diversified portfolio to capitalize on positive trends within the healthcare sector, including increasing demand for robotic-assisted surgery and advancing med-tech solutions.
Bull says
- ↑Q1 organic sales rose 10.1% YoY; full-year organic growth guidance lifted to 8–9.5%.
- ↑Adjusted EPS hit $2.84 (+13.6% YoY); gross margin improved to 65.5%, operating margin to 22.9%.
- ↑Record Mako installations drive utilization; 2M robotic procedures boost ortho market share.
- ↑Amplitude Vascular acquisition on track, adding vascular solutions and synergy potential.
- ↑Strong order backlog and healthy hospital CapEx underpin sustained capital demand.
- ↑High profitability and large market presence signal robust operations and stability.
Bear says
- ↓Cyber breach disrupted operations, slowing medical segment sales rebound.
- ↓Tariff increases and supply-chain strain could compress gross margin gains.
- ↓Analyst earnings revisions are trending downward, clouding near-term outlook.
- ↓31 insider stock sales, zero purchases in six months, signal caution.
- ↓Low earnings yield and negative momentum factors raise valuation concerns.
- ↓Rising competition in robotic surgery risks eroding Stryker’s market share.
Investment themes with SYK
Devices and instruments for medical treatment
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- As of the week of April 1st, we were fully operational across our global manufacturing network as we continue to meet demand and support patient care.
- we remain encouraged by the solid fundamentals in the markets we serve and remain well positioned within them.
- On the M&A front, we recently announced the agreement to acquire amplitude vascular systems that we expect to close in the second quarter.
Bear points
- The cyber incident had a big impact on our results and affected each of our businesses differently given their varied go-to-market models and processes to record revenue.
- This resulted in distortions in our first quarter results that will normalize over the course of the year.
- Adjusted earnings per share of $2.60 was down 24 cents or minus 8.5% from 2025. This decline was driven by limited sales growth and lost manufacturing absorption related to the cyber incident, as well as tariffs and increased interest expense.